济南高新发展股份有限公司 独立董事工作制度 济南高新发展股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善法人治理结构，规范公司独立董事行为，充分 发挥独立董事在公司治理中的作用，促进提高公司质量，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、中国证券监督管理委员会（简 称"中国证监会"）《上市公司独立董事管理办法》、《上海证券交易所股票 上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，结合公司章程有关内容及公司实际情况，制定本制度。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他 可能影响其进行独立客观判断关系的董事。 独立董事应当独立履行职责，不受上市公司及其主要股东、实际控制 人等单位或者个人影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照 法律、行政法规、中国证监会规定、上海证券交易所业务规则和公司章程 的规定，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询 作用，维护公司整体利益，保护中小股东合法权益。公司应当为独立董事 依法 ...

济南高新发展股份有限公司 董事会提名委员会实施细则 济南高新发展股份有限公司 董事会提名委员会实施细则 第一章 总则 第一条 为规范公司董事和高级管理人员的选聘，优化董事会组成， 完善公司治理结构，根据《中华人民共和国公司法》、《上市公司治理准则》、 公司章程及其他有关规定,公司特设立董事会提名委员会，并制定本实施 细则。 第二条 董事会提名委员会是董事会按照股东大会决议设立的专门工 作机构，主要负责对公司董事和经理人员的人选、选择标准和程序进行选 择并提出建议。提名委员会在董事会领导下开展工作，对董事会负责。 第二章 人员组成 第三条 提名委员会成员由三至五名董事组成，其中独立董事人数过 半数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一提名，并由董事会选举产生。 第五条 提名委员会设主任委员（召集人）一名，由独立董事委员担 任，负责主持委员会工作；主任委员在委员内选举,并报请董事会批准产 生。 第六条 提名委员会任期与董事会任期一致，委员任期届满,连选可以 连任。期间如有委员不再担任公司董事职务，自动失去委员资格，并由委 员会根据上述第三至第五条规定补足委员人数。 1 济 ...

证券代码：600807 证券简称：济南高新 公告编号：临2023-067 济南高新发展股份有限公司 关于收到山东证监局警示函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司近日收到中国证券监督管理委员会山东监管局出具的《关于对济南高新 发展股份有限公司及相关责任人员采取出具警示函措施的决定》（【2023】84 号，以下简称"警示函"），现将相关内容公告如下： 二、相关情况说明 公司已于2023年8月18日召开了第十一届董事会第五次临时会议、第十一届 监事会第三次临时会议，审议通过了《关于审议前期会计差错更正的议案》，对 相关事项进行了整改，目前已整改完毕，具体详见公司于2023年8月19日披露的 《关于前期会计差错更正的公告》，本次会计差错更正仅涉及2023年一季度合并 财务报表部分项目，不会对公司总资产、净资产、利润总额、净利润和归属于上 市公司股东净利润产生影响。 公司及相关人员对上述问题高度重视，将认真吸取教训，切实加强对《证券 法》、《上市公司信息披露管理办法》等法律法规及规范性文件的学习，进一步 增强合规 ...

第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员 （简称"经理人员"）的考核和薪酬管理制度,完善公司治理结构，根据《中 华人民共和国公司法》、《上市公司治理细则》、公司章程及其他有关规定， 公司特设立董事会薪酬与考核委员会，并制定本实施细则。 第二条 薪酬与考核委员会是董事会按照股东大会决议设立的专门工 作机构，主要负责制定公司董事及经理人员的考核标准并进行考核；负责 制定、审查公司董事及经理人员的薪酬政策与方案，对董事会负责。 第三条 本细则所称董事是指在本公司支取薪酬的正副董事长、董事， 经理人员是指董事会聘任的总经理、副总经理、董事会秘书及由总经理提 请董事会认定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三至五名董事组成，其中独立董事 人数过半数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或 者全体董事的三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员（召集人）一名，由独立董事 委员担任，负责主持委员会工作；主任委员在委员内选举，并报请董事会 批准产生。 济南高新发展股份有限公司 董事会薪酬与考核委员会实施细则 ...

济南高新发展股份有限公司 董事会审计委员会实施细则 济南高新发展股份有限公司 董事会审计委员会实施细则 第一章 总则 第一条 为强化公司董事会决策功能，完善公司治理结构，根据《中 华人民共和国公司法》、《上市公司治理准则》、《上海证券交易所上市公 司自律监管指引第 1 号——规范运作》、公司章程及其他有关规定，公司 特设立董事会审计委员会，并制定本实施细则。 第二条 董事会审计委员会是根据公司股东大会决议所设立的，是董 事会下设的专门工作机构，主要负责审核公司财务信息及其披露、监督及 评估内外部审计工作和内部控制工作。 第二章 人员组成 第三条 审计委员会成员由三至五名董事组成,应当为不在上市公司 担任高级管理人员的董事。委员中独立董事占半数以上，且至少有一名独 立董事为专业会计人士。 第四条 审计委员会成员由董事长、二分之一以上独立董事或三分之 一以上董事提名，由董事会选举产生。 第五条 审计委员会设主任委员（召集人）一名,由具有会计专业背景 的独立董事委员担任,负责主持委员会工作；主任委员在委员内选举,并报 请董事会批准产生。 第六条 审计委员会任期与董事会一致，委员任期届满，连选可以连 任。期间如有委员 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥102,696,914.56, a decrease of 78.22% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was -¥8,955,743.29, representing a decline of 120.80% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥19,850,094.16, down 123.48% from the previous year[5] - Total operating revenue for the first three quarters of 2023 was ¥504,153,997.25, a decrease of 57.8% compared to ¥1,192,291,710.47 in the same period of 2022[21] - Net profit for the first three quarters of 2023 was -¥43,256,298.07, an improvement from -¥225,078,517.85 in the same period of 2022[22] - The company reported a total comprehensive loss of -¥56,036,341.00 for the first three quarters of 2023, compared to -¥231,922,548.68 in 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,397,885,395.66, a decrease of 15.05% compared to the end of the previous year[6] - The company's total assets amounted to ¥3,397,885,395.66 as of the end of the third quarter of 2023, down from ¥3,999,911,482.83 at the end of 2022[19] - Total liabilities decreased to ¥2,619,675,407.46 from ¥3,165,836,969.57, indicating a decline of about 17.2%[18] - The company's equity attributable to shareholders decreased to ¥279,235,835.79 from ¥350,493,511.05 year-over-year[19] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥139,899,215.76, indicating a significant cash outflow[6] - Operating cash flow for Q3 2023 was -139,899,215.76, compared to -330,149,581.99 in the same period last year, indicating an improvement[26] - Total cash inflow from operating activities was 833,021,279.37, while cash outflow was 972,920,495.13, resulting in a net cash flow from operating activities of -139,899,215.76[26] - Cash received from other operating activities was 434,405,199.81, compared to 439,839,375.63 in the previous year[26] - Cash paid for purchasing goods and services was 346,419,225.22, compared to 958,023,781.40 in the same period last year[26] - The ending cash and cash equivalents balance for Q3 2023 was 221,588,597.40, down from 640,222,839.93 at the beginning of the period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,166[12] - The largest shareholder, Jinan High-tech Urban Construction Development Co., Ltd., holds 142,307,521 shares, accounting for 16.09% of total shares[12] - The company has a significant amount of pledged shares, with 44,575,988 shares pledged by the largest shareholder[12] Inventory and Investments - The company reported a total of 792,248,835.79 in inventory, down from 901,506,458.45, a decrease of approximately 12.1%[17] - The company has ongoing investments in long-term equity, totaling ¥264,576,902.50, slightly down from ¥269,337,707.91[17] Earnings Per Share - The basic and diluted earnings per share for Q3 2023 were both -¥0.01, with no applicable data for the previous year[6] - Basic and diluted earnings per share for the third quarter of 2023 were both -¥0.06, an improvement from -¥0.29 in the same quarter of 2022[23] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥7,801,391.62, a decrease of 44.3% compared to ¥13,999,667.34 in 2022[21] Financial Expenses - Financial expenses for the first three quarters of 2023 were ¥18,959,754.92, significantly lower than ¥77,774,263.22 in the same period of 2022[22] Non-Recurring Gains - The company reported non-recurring gains of ¥10,316,005.67 from the disposal of non-current assets during the reporting period[8] Revenue and Costs - Total operating costs for the first three quarters of 2023 were ¥526,015,418.12, down from ¥1,096,368,575.32 in 2022, reflecting a reduction of 52.0%[21]

上 海 证 券 交 易 所 上证公监函〔2023〕0216 号 关于对济南高新发展股份有限公司及 有关责任人予以监管警示的决定 当事人： 济南高新发展股份有限公司，A 股证券简称：济南高新，A 股证 券代码：600807； 雷学锋，济南高新发展股份有限公司时任财务总监。 经查明，2023 年 8 月 18 日，济南高新发展股份有限公司（以下 简称公司）披露关于前期会计差错更正的公告。公告显示，公司对 子公司山东瑞蚨祥贸易有限公司（以下简称瑞蚨祥公司）开展的黄 金贸易销售业务进行了重新梳理，鉴于瑞蚨祥公司更倾向于代理人 角色,公司将上述业务由"总额法"调整为"净额法"确认营业收 入。会计差错更正后，2023 年一季报中，调减营业收入 2239.11 万 元，调减营业成本 2239.11 万元，分别占更正后金额 11.54%、 17.47%。 定期报告是投资者高度关注的事项，可能对公司经营发展和投 资者决策产生重要影响。公司理应根据会计准则对财务数据进行客 观、审慎地核算，并准确对外披露。公司前期对黄金贸易销售业务 1 的收入确认存在会计处理差错，导致相关定期报告财务数据披露不 准确。上述行为违反了《公开发行证券 ...

证券代码：600807 证券简称：济南高新 编号：临2023-065 济南高新发展股份有限公司 关于控股子公司向银行申请项目贷款获批 暨提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 ● 近期，公司控股子公司山东艾克韦生物技术有限公司（简称"艾克韦生物"）向中 国工商银行股份有限公司济南高新支行（简称"工行高新支行"）申请项目贷款 9,000 万元 获批并签署《固定资产借款合同》，款项用于艾克韦生物重大流行性传染病防控技术及产业 化基地项目建设，艾克韦生物以该项目部分在建工程提供抵押担保，公司按照对艾克韦生物 的持股比例 27.2202%履行保证担保责任。 ● 除本次担保外，公司为艾克韦生物提供的担保余额为 0。 为满足公司控股子公司艾克韦生物项目建设资金需要，近期，艾克韦生物向工行高新支 行申请项目贷款9,000万元获批并签署《固定资产借款合同》，借款用于艾克韦生物重大流 行性传染病防控技术及产业化基地项目建设，借款利率为5年以上贷款市场报价利率减30个 基点（现为3.90%/年），借款期 ...

证券代码：600807 证券简称：济南高新 公告编号：临 2023-066 济南高新发展股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 9 月 12 日(星期二) 至 9 月 18 日(星期一)前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱600807@vip.163.com 进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 济南高新发展股份有限公司（以下简称"公司"）已于 2023 年 8 月 30 日披 露 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果、财务状况，公司计划于 2023 年 9 月 19 日下午 14:00-15:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2023 年半年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥401,457,082.69, a decrease of 44.30% compared to ¥720,758,018.97 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was -¥46,940,056.54, improving from -¥293,179,178.50 in the previous year[18]. - The net cash flow from operating activities was -¥179,221,195.56, compared to -¥168,370,583.08 in the same period last year[18]. - The total assets at the end of the reporting period were ¥3,516,429,516.14, down 12.09% from ¥3,999,911,482.83 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 16.99% to ¥290,954,034.45 from ¥350,493,511.05 at the end of the previous year[18]. - The basic earnings per share for the first half of 2023 was -¥0.05, compared to -¥0.34 in the same period last year[19]. - The weighted average return on net assets improved to -14.58% from -100.47%, an increase of 85.89 percentage points[20]. - The company reported a decrease in the diluted earnings per share to -¥0.05 from -¥0.34 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was -¥29,434,006.54, compared to -¥45,248,819.86 in the previous year[18]. - The total operating income decreased by 44.30% to CNY 401.46 million compared to the same period last year[46]. - The operating costs also decreased by 47.78% to CNY 277.47 million, primarily due to the divestment of mining operations[48]. - The company reported a net loss of ¥168.68 for Wangsheng Ecology, a 112.55% decrease compared to the previous year's profit of ¥1,344.17, primarily due to increased credit impairment losses[70]. - The company reported a net loss of 18 million RMB for the first half of 2023, with total assets amounting to 42.5 million RMB[107]. - The net loss for the period was reported at 1,640.43 million RMB, indicating a challenging financial environment[156]. - The company recorded a comprehensive loss of 13,583.00 million RMB during the first half of 2023, highlighting ongoing financial difficulties[159]. Market and Industry Insights - The global in vitro diagnostics (IVD) market was valued at $127.4 billion in 2022, with a projected compound annual growth rate (CAGR) of 1.91% until 2027[25]. - China's IVD market grew from ¥45 billion in 2016 to ¥124.3 billion in 2021, maintaining a CAGR of 22.5%[25]. - The independent medical laboratory (ICL) industry in China is expected to reach a market size of ¥51.3 billion by 2026, with a CAGR of 18.2% from 2021 to 2026[26]. - The real estate market is expected to experience a gradual recovery in the second half of 2023, supported by favorable policies and easing financing difficulties[29]. Business Operations and Strategy - The company focuses on the life and health core business, aiming to become a leading service provider in the domestic life and health industry[30]. - The company is committed to continuous product innovation and development in the field of molecular diagnostics and third-party medical testing services[30]. - The landscaping and municipal construction business is providing comprehensive ecological restoration and construction services, contributing to the company's revenue growth[33]. - The company is actively expanding its third-party medical testing services, including COVID-19 nucleic acid testing for enterprises and schools[32]. - The company has developed over 150 types of molecular diagnostic reagents for major infectious diseases, covering 80% of nationally mandated infectious diseases[30]. - The company has developed a new generation of high-throughput fully automated nucleic acid detection systems, enhancing its product offerings in the molecular diagnostics sector[31]. - The company is focusing on expanding its core business in life health, with plans to enhance its industry chain and core competitiveness[72]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its portfolio[156]. Governance and Compliance - The company guarantees the independence of its senior management and financial personnel, ensuring no dual roles in controlled entities[85]. - The company will minimize related party transactions post-restructuring, ensuring compliance with market principles and fair pricing[85]. - The company has established a governance structure to ensure independence and prevent asset and fund occupation[87]. - The company has not disclosed any significant related party transactions during the reporting period[94]. - The company has not reported any major guarantees during the reporting period[98]. - The company has not disclosed any ongoing or unresolved major contracts[97]. - The company has not reported any litigation or arbitration matters that are not disclosed or have subsequent developments[93]. Legal and Litigation Matters - The company is involved in significant litigation matters, including a dispute with Shenzhen Fu'ao Kang Fund Management Co., which has been resolved with the court ruling that the guarantee contract is not enforceable[90]. - A settlement has been reached in the case involving Yang Haoyu and Yong'an Real Estate, with compensation based on a principal amount of CNY 40,258,125, calculated according to the prevailing loan interest rates[90]. - The company is actively pursuing legal actions to recover debts and enforce court rulings[91]. - The company has been involved in multiple legal disputes, indicating ongoing challenges in its financial operations[91]. Shareholder and Capital Structure - The company initiated a private placement of shares at CNY 2.44 per share, aiming to raise up to CNY 400 million to supplement working capital[43]. - The total number of ordinary shareholders at the end of the reporting period is 41,564[104]. - The largest shareholder, Jinan High-tech City Construction Development Co., Ltd., holds 142,307,521 shares, accounting for 16.09% of the total shares[106]. - The company has not experienced any changes in its total share capital or share structure during the reporting period[103]. - The company has suspended the implementation of its stock incentive plan due to an audit report from 2017 that was issued with a disclaimer of opinion[109]. - The company has terminated its stock incentive plan, which was triggered by the audit report, and is currently pausing subsequent share repurchase and cancellation procedures[110]. Financial Position and Assets - The company's total assets decreased to CNY 2,249,414,091.50 from CNY 2,547,040,791.13, reflecting a decline of 11.7%[122]. - Total liabilities decreased to CNY 1,612,753,984.22 from CNY 1,857,040,952.18, a reduction of 13.2%[122]. - The company's equity decreased to CNY 636,660,107.28 from CNY 689,999,838.95, a decline of 7.7%[122]. - The company’s total equity decreased to RMB 796,239,548.77, down 4.5% from RMB 834,074,513.26 at the end of 2022[118]. - The company’s cash and cash equivalents decreased by 65.06% to CNY 272.88 million, mainly due to loan repayments and litigation costs[56]. Research and Development - The company’s research and development expenses decreased by 32.95% to CNY 6.41 million, reflecting reduced investment in R&D[47]. - The company has over 100 patents/software copyrights and multiple medical device registration certificates, showcasing its strong innovation capabilities[38]. Accounting and Financial Reporting - The company’s financial statements are prepared based on the accrual basis of accounting, in accordance with the relevant accounting standards[171]. - The company adheres to the accounting standards, ensuring that the consolidated financial statements accurately reflect its financial position as of June 30, 2023, and the operating results for the first half of 2023[174]. - The company's accounting period follows the calendar year, from January 1 to December 31[175].